Bayer Ready To File Elinzanetant After It Clears Third Phase III Hurdle

Will Compete With Sluggish Astellas Competitor

Bayer will submit its non-hormonal treatment for vasomotor symptoms associated with menopause for approvals this year, still eyeing €1bn-plus in peak sales despite a rival’s slow start.

Tired, stressed mature business woman suffering from neck pain, working from home office, sitting at table
Elinzanetant reduces hot flashes and may improve sleep in menopausal women • Source: Shutterstock

Bayer AG reported positive topline results from the third and final Phase III clinical trial of its non-hormonal treatment for vasomotor symptoms (VMS) associated with menopause on 19 March, declaring that it will now seek approvals for elinzanetant in multiple markets. This will pit the drug against a rival product, Astellas Pharma, Inc.’s Veozah (fezolinetant), which to date has seen sluggish sales that prompted the Japanese drug maker to lower its forecast for the product.

More from Clinical Trials

More from R&D